Catherine Spiker, DO
Family Medicine · Newport, TNNPI 1760744726
Payments from drug & device makers
Across 1,227 payments — averaging $14.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$2K
- AstraZeneca$2K
- GSK$1K
- Pfizer$783
- Biohaven Pharmaceuticals, Inc.$770
- plus $9K from 54 others
What the payments were for
- Food & beverage$18,174100%
- Education$660%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$373
- BREZTRI$228
- SYMBICORT$145
- TRELEGY ELLIPTA$110
- Penumbra System$110
- XARELTO$100
How this compares
$18,241 in reported general payments places this provider in the 95th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 279 | $429,929 |
| IngrezzaValbenazine Tosylate | 16 | $204,245 |
| VraylarCariprazine Hcl | 127 | $203,935 |
| Humira(Cf) PenAdalimumab | 13 | $180,369 |
| EliquisApixaban | 198 | $177,930 |
| JardianceEmpagliflozin | 151 | $167,944 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 154 | $150,032 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 97 | $141,967 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 75 | $141,959 |
| OzempicSemaglutide | 90 | $134,167 |
| RexultiBrexpiprazole | 81 | $131,552 |
| Humira PenAdalimumab | 15 | $102,473 |
| Enbrel SureclickEtanercept | 12 | $94,260 |
| FarxigaDapagliflozin Propanediol | 71 | $90,649 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 242 | $74,655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $473 | $501,762320 claims |
| GSKTrelegy Ellipta, Arexvy, Anoro Ellipta, Shingrix | $1,331 | $290,940545 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Brilinta, Symbicort | $1,795 | $274,561275 claims |
| AbbVieVraylar, Linzess | $1,996 | $259,141179 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $261 | $204,24516 claims |
| PfizerEliquis, Nurtec Odt | $783 | $202,906216 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat | $623 | $198,758180 claims |
| Novo NordiskOzempic, Wegovy | $2,156 | $155,393102 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $712 | $131,55281 claims |
| BayerKerendia | $284 | $71,81854 claims |
| Johnson & JohnsonXarelto | $694 | $54,85464 claims |
| NovartisEntresto | $320 | $53,40551 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Newport
- Kabir Harricharan SinghNewport$49K
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.